[go: up one dir, main page]

WO2007145589A8 - Peptides capables de se lier à un peptide bêta-amyloïde - Google Patents

Peptides capables de se lier à un peptide bêta-amyloïde Download PDF

Info

Publication number
WO2007145589A8
WO2007145589A8 PCT/SE2007/050424 SE2007050424W WO2007145589A8 WO 2007145589 A8 WO2007145589 A8 WO 2007145589A8 SE 2007050424 W SE2007050424 W SE 2007050424W WO 2007145589 A8 WO2007145589 A8 WO 2007145589A8
Authority
WO
WIPO (PCT)
Prior art keywords
amyloid
binding
peptides
beta peptide
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE2007/050424
Other languages
English (en)
Other versions
WO2007145589A1 (fr
Inventor
Per Arvidsson
Jan Johansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2007145589A1 publication Critical patent/WO2007145589A1/fr
Anticipated expiration legal-status Critical
Publication of WO2007145589A8 publication Critical patent/WO2007145589A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne de nouveaux peptides capables de se lier à un peptide bêta-amyloïde, l'atome Nα d'au moins un résidu d'acide aminé étant substitué avec un substituant qui produit un encombrement stérique empêchant toute autre liaison du peptide bêta-amyloïde. L'invention concerne en outre l'utilisation desdits peptides dans le domaine médical et des compositions pharmaceutiques destinées au traitement de la maladie d'Alzheimer.
PCT/SE2007/050424 2006-06-15 2007-06-15 Peptides capables de se lier à un peptide bêta-amyloïde Ceased WO2007145589A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0601310-6 2006-06-15
SE0601310 2006-06-15

Publications (2)

Publication Number Publication Date
WO2007145589A1 WO2007145589A1 (fr) 2007-12-21
WO2007145589A8 true WO2007145589A8 (fr) 2009-07-23

Family

ID=38832008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/050424 Ceased WO2007145589A1 (fr) 2006-06-15 2007-06-15 Peptides capables de se lier à un peptide bêta-amyloïde

Country Status (1)

Country Link
WO (1) WO2007145589A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034739B2 (en) 2015-11-13 2021-06-15 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566020A (en) 2005-09-09 2012-08-31 Novartis Ag Prion-specific peptoid reagents
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
EP2149380A1 (fr) * 2008-07-29 2010-02-03 Medivet Pharma, S.L. Compositions d'immunothérapie vétérinaire pour le disfonctionnement cognitif associé à l'âge
EP2344545A4 (fr) * 2008-10-06 2012-10-03 Commw Scient Ind Res Org Structure cristalline de peptide bêta-amyloïde
WO2011156003A2 (fr) * 2010-06-09 2011-12-15 New York University Oligomères peptoïdes et synthétiques, compositions pharmaceutiques et procédés d'utilisation de ceux-ci
EP3049099B1 (fr) * 2013-09-26 2020-06-17 Forschungszentrum Jülich GmbH Peptides se liant aux bêta-amyloïdes et leur utilisation pour le traitement et le diagnostic de la maladie d'alzheimer
EP3684784B1 (fr) 2017-09-20 2024-03-27 Council of Scientific and Industrial Research Inhibiteurs peptidiques puissants de l'agrégation de protéines

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
KR20060054174A (ko) * 2003-03-28 2006-05-22 센토코 인코포레이티드 항-아밀로이드 항체, 조성물, 방법 및 용도

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11034739B2 (en) 2015-11-13 2021-06-15 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada Ligand-guided phagocytosis based therapy for treatment of Alzheimer's disease and other neurodegenerative diseases

Also Published As

Publication number Publication date
WO2007145589A1 (fr) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2007145589A8 (fr) Peptides capables de se lier à un peptide bêta-amyloïde
WO2008118017A3 (fr) Peptides dérivés de prame et compositions immunogènes comprenant ceux-ci
WO2008081701A1 (fr) Peptide wt1 à restriction hla-a*1101 et composition pharmaceutique le contenant
WO2004092146A3 (fr) Acides phenylalcanoiques substitues
EP2390265A3 (fr) Dérivé de peptide insulinotropique dont l'acide aminé n-terminal est modifié
WO2008050101A3 (fr) Composés chimiques
WO2004078777A3 (fr) Proteines protegees contre la dipeptidylpeptidase
EP2360258A3 (fr) Polypeptides d'aprotinine pour transporter un composé à travers une barriere sang-cerveau
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
WO2007009894A3 (fr) Nouveaux peptides utilises dans le traitement de l'obesite
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
WO2005116051A3 (fr) Peptides specifiques de tumeurs, se fixant sur des molecules cmh
WO2005023866A3 (fr) Peptides permettant d'inhiber l'activation du complement
WO2010115843A3 (fr) Composition pharmaceutique
MX2009004467A (es) Compuestos benzoilo amino heterociclilo como activadores de la glucoquinasa (glk).
WO2004099168A3 (fr) Acides carboxyliques substitues
ZA200702318B (en) Nanobodies against amyloid-beta and polypeptides comprising the same for the treatment of degenerative neual diseases such as alzheimer's disease
SI2010563T1 (sl) Sintetična MeCP2 sekvenca za proteinsko nadomestno terapijo
WO2008066626A3 (fr) Procédés pour le traitement de troubles en rapport avec aβ, et compositions pour ceux-ci
WO2007095661A8 (fr) Peptides et derives peptidiques, leur production et leur utilisation dans la preparation d'une composition pharmaceutique active therapeutiquement et/ou a titre preventif
WO2006055725A3 (fr) Acides amino carboxyliques substitues
WO2008087189A3 (fr) Nouveaux peptides pour le traitement de l'obésité
WO2008135661A3 (fr) Utilisation de la citrulline pour pour le traitement de pathologies liees a une augmentation de la carbonylation des protéines
EP3026057A3 (fr) Compositions pour la prévention et le traitement de maladies neurodégénératives
WO2008057599A3 (fr) Procédés de traitement de troubles associés à l'abeta et compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07748584

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07748584

Country of ref document: EP

Kind code of ref document: A1